| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce760c0a9ca5600bb8287701e5563d57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_840860e91269ae41a4fec95d16dac49c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate |
2010-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee1068fe07b26ac11e3602c11e8c76fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dadc53e824bbea7101b81c8e4de86b |
| publicationDate |
2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010179163-A1 |
| titleOfInvention |
Nol3 is a predictor of patient outcome |
| abstract |
The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014357684-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9533980-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10865252-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10329626-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441654-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021148396-A1 |
| priorityDate |
2009-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |